ADRENALINE-LINK 1:10,000 1mg/10mL adrenaline (epinephrine) acid tartrate injection BP pre filled syringe Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

adrenaline-link 1:10,000 1mg/10ml adrenaline (epinephrine) acid tartrate injection bp pre filled syringe

link medical products pty ltd t/a link pharmaceuticals - adrenaline (epinephrine) acid tartrate, quantity: 182 microgram/ml (equivalent: adrenaline (epinephrine), qty 100 microgram/ml) - injection, solution - excipient ingredients: sodium citrate dihydrate; sodium metabisulfite; dilute hydrochloric acid; water for injections; sodium chloride; citric acid monohydrate - adrenaline 1:10,000 is used as an adjunct in the management of cardiac arrest.

ADRENALINE-LINK 1:10,000 1mg/10mL adrenaline (epinephrine) acid tartrate injection BP ampoule Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

adrenaline-link 1:10,000 1mg/10ml adrenaline (epinephrine) acid tartrate injection bp ampoule

link medical products pty ltd t/a link pharmaceuticals - adrenaline (epinephrine) acid tartrate, quantity: 182 microgram/ml (equivalent: adrenaline (epinephrine), qty 100 microgram/ml) - injection, solution - excipient ingredients: citric acid monohydrate; sodium metabisulfite; sodium chloride; sodium citrate dihydrate; water for injections; dilute hydrochloric acid - adrenaline 1:10,000 is used as an adjunct in the management of cardiac arrest.

COLISTIN LINK colistimethate sodium (equivalent to colistin 150 mg, 4,500,000 IU)  powder for injection vial Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

colistin link colistimethate sodium (equivalent to colistin 150 mg, 4,500,000 iu) powder for injection vial

link medical products pty ltd t/a link pharmaceuticals - colistimethate sodium (equivalent: colistin, qty iu) - injection, powder for - excipient ingredients: - colistin link parental is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitve strains of pseudomonas aeruginosa. this antibiotic is not indicated for infections due to proteus and neisseria. colistin link parental has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa. pending results of appropriate bacterialogic cultures and sensitvity tests, colistin link parental may be used to initiate therapy in serious infections that are suspected due to gram-negative organisms.

ADRENALINE-LINK Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

adrenaline-link

link medical products pty ltd t/a link pharmaceuticals - adrenaline acid tartrate -

ADRENALINE-LINK 1:1,000 1mg/1mL adrenaline (epinephrine) acid tartrate injection BP ampoule Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

adrenaline-link 1:1,000 1mg/1ml adrenaline (epinephrine) acid tartrate injection bp ampoule

link medical products pty ltd t/a link pharmaceuticals - adrenaline (epinephrine) acid tartrate, quantity: 1.82 mg/ml (equivalent: adrenaline (epinephrine), qty 1 mg/ml) - injection, solution - excipient ingredients: sodium chloride; sodium metabisulfite; hydrochloric acid; sodium hydroxide; water for injections - indications as at 27 june 2003: adrenaline 1:1,000 is the drug of choice in the emergency treatment of acute severe anaphylactic reactions due to insect bites, drugs and other allergens. it may also be used for the symptomatic relief of respiratory distress due to bronchospasm.

Colistin-Link New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

colistin-link

link pharmaceuticals ltd - colistimethate sodium 384.6 mg/ml - powder for injection - 150 mg/2ml - active: colistimethate sodium 384.6 mg/ml - the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli; particularly when the infection is caused by sensitive strains of pseudomonas aeruginosa, and the following gram-negative organisms; aerobacter aerogenes, escherichia coli, klebsiella pneumoniae. pending results of appropriate bacteriologic cultures and sensitivity tests, colistimethate sodium may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms.

Dapsone (Link) New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

dapsone (link)

link pharmaceuticals ltd - dapsone 100mg - tablet - 100 mg - active: dapsone 100mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose - dermatitis herpetiformis.

Dapsone (Link) New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

dapsone (link)

link pharmaceuticals ltd - dapsone 25mg - tablet - 25 mg - active: dapsone 25mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose - dermatitis herpetiformis.

ERYTHROMYCIN-LINK erythromycin 1g (as lactobionate) powder for injection vial Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

erythromycin-link erythromycin 1g (as lactobionate) powder for injection vial

link medical products pty ltd t/a link pharmaceuticals - erythromycin lactobionate, quantity: 1.4882 g/g (equivalent: erythromycin, qty 1 g) - injection, powder for - excipient ingredients: - oral erythromycin is not considered to be the antibiotic of choice in severely ill patients.,erythromycin-link (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time.,? upper respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).,? lower respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae).,? respiratory tract infections due to mycoplasma pneumoniae.,? skin and s